Choi Sung Wook, Kim Juhee, Lee Jae Hoon, Kim Seul Ki, Lee Sa Ra, Kim Sung Hoon, Chae Hee Dong
Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
J Menopausal Med. 2022 Apr;28(1):1-8. doi: 10.6118/jmm.21036.
The coronavirus disease 2019 (COVID-19) pandemic has impacted the medical, social, and reproductive health of millions of people since its outbreak. The causative virus transmits, reproduces, and manifests through the respiratory tract. COVID-19 can invade any system of the body, including the cardiovascular and endocrine systems, through a secondary immune response. In particular, because the fatality rate is high in those over the age of 50 years, special attention is required during the medical care of this population. However, considering the benefit of therapy and the risk of COVID-19, high-quality evidence regarding individualized management in relation to hormone therapy is still insufficient in the field of gynecology. Furthermore, this review aims to serve as a reference for clinical application by analyzing and summarizing the results of studies reported to date regarding female hormone therapy in the context of the COVID-19 pandemic.
自2019年冠状病毒病（COVID-19）大流行爆发以来，已对数以百万计的人的医疗、社会和生殖健康产生了影响。致病病毒通过呼吸道传播、繁殖并显现症状。COVID-19可通过继发性免疫反应侵袭身体的任何系统，包括心血管和内分泌系统。特别是，由于50岁以上人群的死亡率较高，在对这一人群进行医疗护理时需要特别关注。然而，考虑到治疗的益处和COVID-19的风险，在妇科领域，关于激素治疗个体化管理的高质量证据仍然不足。此外，本综述旨在通过分析和总结迄今为止报道的在COVID-19大流行背景下女性激素治疗的研究结果，为临床应用提供参考。
